Denis Maillet

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Thomas Powles, Mark Kockx, Alejo Rodríguez‐Vida et al. · Nature Medicine · 2019 · 571 citations · Full text

Medicine, Oncology, Urology +13

Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

Bernadett Szabados, Mark Kockx, Zoe J. Assaf et al. · European Urology · 2022 · 190 citations · Full text

Medicine, Oncology, Urology +13

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Yann Vano, Réza Elaidi, Mostefa Bennamoun et al. · The Lancet Oncology · 2022 · 136 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

<i><scp>DICER</scp>1</i> and <i><scp>FOXL</scp>2</i> mutations in ovarian sex cord–stromal tumours: a <scp>GINECO</scp> Group study

Thibault Goulvent, Isabelle Ray‐Coquard, Stéphane Borel et al. · Histopathology · 2015 · 110 citations

Veterinary Medicine, Genetics, Oncology +11

Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy

G. Androdias, Denis Maillet, Romain Marignier et al. · Neurology · 2011 · 97 citations

Pharmacy, Neurology, Pharmacotherapy +15